Abstract:Background Ovarian cancer is the most common gynecological malignancy and is difficult to manage due to the emergence of resistance to various chemotherapeutic drugs. New efforts are urgently awaited. Aspirin, which is traditionally considered a nonsteroidal anti-inflammatory drug (NSAID), has been reported to exert potential chemopreventive effects. Therefore, we aimed to investigate the anticancer effect and explore the underlying molecular mechanisms of aspirin on epithelial ovarian cancer (EOC) cells. Methods We conducted wound healing, transwell migration, EdU cell proliferation, colony formation and apoptosis detection assays to observe the effects of aspirin on the migration, proliferation and apoptosis of EOC cells (A2870, Caov-3, and SK-OV-3). EOC cells were treated with a combination of aspirin and cisplatin (CDDP) to observe the effect of aspirin on enhancing CDDP sensitivity. Orthotopic xenograft models of ovarian cancer established with A2780-Luciferase-GFP cells were applied to compare tumor growth inhibition in the control, CDDP and CDDP plus aspirin groups through in vivo imaging, which can be used to continuously monitor tumor growth. The expression and acetylation levels of p53 in EOC cells treated with aspirin were determined using western blotting, and p53 acetylation levels were examined in tumors harvested from the transplanted mice. Quantitative real-time PCR was used to assess the mRNA expression of p53 target genes. Results Aspirin inhibited migration and proliferation and induced apoptosis in EOC cell lines in a concentration-dependent manner. In vitro, aspirin enhanced the sensitivity of EOC cells to CDDP by increasing its inhibitory effect on proliferation and its effect on inducing apoptosis. In vivo, the differences in the tumor growth inhibition rates among the different CDDP experimental groups were statistically significant ( p < 0.05). Aspirin did not affect p53 protein expression but increased the p53 acetylation level in a concentration-dependent manner. In addition, the mRNA levels of CDKN1A, BAX, FOXF1, PUMA, and RRAD in EOC cells were significantly increased by the aspirin treatment. Conclusions Aspirin inhibits tumor progression and enhances the CDDP sensitivity of EOC cells. These antitumor effects of aspirin might be mediated by p53 acetylation and subsequent activation of p53 target genes.

Aspirin Attenuates YAP and Β-Catenin Expression by Promoting Β-Trcp to Overcome Docetaxel and Vinorelbine Resistance in Triple-Negative Breast Cancer.

Aspirin Inhibits Cancer Metastasis and Angiogenesis Via Targeting Heparanase

Aspirin Disrupts the Mtor-Raptor Complex and Potentiates the Anti-Cancer Activities of Sorafenib Via Mtorc1 Inhibition.

Aspirin Regulation of C-Myc and Cyclind1 Proteins to Overcome Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells

Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.

Knockdown of TAZ Modifies Triple-Negative Breast Cancer Cell Sensitivity to EGFR Inhibitors by Regulating YAP Expression.

Role Of P38 Mapk In Enhanced Human Cancer Cells Killing By The Combination Of Aspirin And Abt-737

Aspirin Prevent Colorectal Cancer Via <i>enterococcus Cecorum</i> -TIGIT <sup>+</sup>treg Cell Axis

[Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy].

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy.

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer

Aspirin Regulates Gemcitabine Resistance in Pancreatic Cancer via Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Reversing Epithelial-mesenchymal Transition

The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study

Dual Inhibition of Wnt and Yes‐associated Protein Signaling Retards the Growth of Triple‐negative Breast Cancer in Both Mesenchymal and Epithelial States

Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway

Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter

Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function

Enhanced Anti-tumor Efficacy of Aspirin Combined with Triptolide in Cervical Cancer Cells

Aspirin Cooperates with P300 to Activate the Acetylation of H3K9 and Promote FasL-mediated Apoptosis of Cancer Stem-Like Cells in Colorectal Cancer